C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Makes New Investment in BioNTech SE (NASDAQ:BNTX)

C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in shares of BioNTech SE (NASDAQ:BNTX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 9,810 shares of the company’s stock, valued at approximately $1,118,000.

Other hedge funds also recently added to or reduced their stakes in the company. Planning Capital Management Corp lifted its holdings in BioNTech by 45,000.0% during the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock worth $54,000 after buying an additional 450 shares in the last quarter. Blue Trust Inc. increased its position in shares of BioNTech by 491.1% in the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after purchasing an additional 388 shares during the last quarter. GAMMA Investing LLC increased its position in shares of BioNTech by 48.2% in the 4th quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock valued at $105,000 after purchasing an additional 300 shares during the last quarter. AlphaCentric Advisors LLC purchased a new stake in shares of BioNTech in the 4th quarter valued at approximately $168,000. Finally, Clear Harbor Asset Management LLC purchased a new stake in shares of BioNTech in the 3rd quarter valued at approximately $210,000. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Stock Up 2.4 %

Shares of NASDAQ:BNTX opened at $122.75 on Wednesday. BioNTech SE has a 1-year low of $76.53 and a 1-year high of $131.49. The stock has a market cap of $29.43 billion, a P/E ratio of -58.45 and a beta of 0.17. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The firm has a fifty day moving average price of $117.32 and a 200 day moving average price of $110.18.

Analyst Ratings Changes

A number of equities research analysts have commented on BNTX shares. Berenberg Bank started coverage on shares of BioNTech in a research report on Tuesday, November 19th. They issued a “buy” rating and a $130.00 price objective on the stock. Wells Fargo & Company assumed coverage on shares of BioNTech in a research report on Wednesday, December 11th. They issued an “overweight” rating and a $170.00 price objective on the stock. TD Cowen dropped their target price on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a research report on Tuesday, November 5th. BMO Capital Markets reaffirmed an “outperform” rating on shares of BioNTech in a research report on Monday, December 2nd. Finally, JPMorgan Chase & Co. dropped their target price on shares of BioNTech from $124.00 to $122.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 26th. Three analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, BioNTech has a consensus rating of “Moderate Buy” and an average target price of $142.72.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.